HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure
Ella Day | July 7, 2025 | News story | Mergers and Acquisitions, Research and Development | AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure
HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac organoid models.
German biotech, biotx.ai, will apply its mendelian randomisation platform to identify new genetic targets causally linked to heart failure. Austria-based HeartBeat.bio will validate these targets using its cardioid drug discovery platform – a human-derived cardiac organoid system that imitates heart structure and disease biology.
Heart failure affects over 30 million people globally and, while treatment options exist, many patients lack therapies targeting the underlying disease mechanisms. The partnership aims to unlock new, genetically validated drug targets and validate them in a human-relevant model, aiming to improve clinical success rates.
HeartBeat.bio holds exclusive rights to pursue drug development or partnerships on validated targets, with biotx.ai eligible for milestones and royalties. The companies will initially focus on cardiomyopathies, myocardial fibrosis and chronic cardiac remodelling – all common features in heart failure.
“Our mission is to transform the way heart failure is treated by combining our human-based drug discovery platform with cutting-edge AI technologies,” said Michael Krebs, CEO of HeartBeat.bio.
“Together, we aim to accelerate the development of disease-modifying therapies for heart failure,” added Marco Schmidt, CEO of biotx.ai.
Ella Day
7/7/25
Related Content
MultiOmic Health and BIO4 Campus sign collaborative Memorandum of Understanding
MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company and BIO4 Campus (BIO4), …
Sanome’s AI tool gains certification for early detection of hospital infections
Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to …
M42 study highlights positive performance of AI model for tuberculosis screening
Healthcare tech company, M42, has published results from one of the largest real-world studies of …
